Skip Navigation



NDT Advance Access published online on November 28, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl690
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/2/342    most recent
gfl690v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aydin, Z.
Right arrow Articles by Rabelink, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aydin, Z.
Right arrow Articles by Rabelink, T. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

New horizons in prevention and treatment of ischaemic injury to kidney transplants

Zeynep Aydin, Anton J. van Zonneveld, Johan W. de Fijter and Ton J. Rabelink

Department of Nephrology, Leiden University Medical Center, Albinusdreef 2, 9600 RC Leiden, The Netherlands

Correspondence and offprint requests to: Ton J. Rabelink, Department of Nephrology, Leiden University Medical Center, Albinusdreef 2, 9600 RC Leiden, The Netherlands. Email: t.rabelink@lumc.nl

Keywords: erythropoietin; glitazones; ischemia-reperfusion injury stem cells; kidney donor

The first 150 words of the full text of this article appear below.



   Introduction
 
Ischaemia–reperfusion injury to the kidney is a major insult in kidney transplantation and is responsible for delayed graft function in post-mortal donation. The incidence has been reported to be approximately one-quarter in kidneys obtained from deceased donors and up to 50% of kidneys after cardiac death procedures (non-heart beating donors). In the latter group, it causes primary graft failure in 10% of the donors [1]. Despite its great clinical relevance, few therapeutic options have evolved over the years to improve recovery of acute ischaemic renal injury or to successfully prevent it. In this review, we will first discuss briefly the pathophysiology of ischaemic injury to the donor kidney and then review new therapeutic options, such as growth factor therapy and cell therapy, with respect to their potential to modulate this pathophysiology.

This review is not a comprehensive and complete review, but rather aims to put the new therapeutic . . . [Full Text of this Article]



   Pathophysiology
 


   New therapeutic options
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. Mehrabi, Zh. A. Mood, M. Sadeghi, B. M. Schmied, S. A. Muller, Th. Welsch, G. Kuttymuratov, M. N. Wente, J. Weitz, M. Zeier, et al.
Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation
Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_8): viii54 - viii60.
[Abstract] [Full Text] [PDF]